Loading
NASDAQHealthcareBiotechnology
Latest quote
$28.70
+$0.33 · +1.16%
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Previous close
$28.70
+$0.33 · +1.16%
After-hours
$28.70
$0.00 · 0.00%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Day range
Current $28.70
52-week range
Current $28.70
Regular session · ET · Market data may be delayed.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Day range
Current $28.70
52-week range
Current $28.70
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI25.4M0.00%2.3T USD0.03%$381.03-0.40%
State Street SPDR S&P Biotech ETFXBI15.3M0.15%10.08B USD0.35%$150.23-0.44%
iShares Russell 2000 ETFIWM14.5M0.02%78.56B USD0.19%$277.7-1.29%
Vanguard Extended Market ETFVXF9.41M0.01%95.4B USD0.05%$233.49-1.56%
iShares Russell 2000 Growth ETFIWO3.18M0.02%14.25B USD0.24%$355.37-1.43%
Schwab U.S. Small-Cap ETFSCHA2.59M0.01%21.7B USD0.03%$32.61-1.47%
Fidelity Fundamental Small-Mid Cap ETFFFSM1.66M0.10%1.44B USD0.43%$34.00-2.02%
T. Rowe Price Small-Mid Cap ETFTMSL1.11M0.04%3.1B USD0.55%$40.94-1.70%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAFidelity Fundamental Small-Mid Cap ETFFFSMT. Rowe Price Small-Mid Cap ETFTMSLAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
